NBIX · XBRL financial data

Neurocrine Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NBIX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	515*	515	590	622	628*	573	688	795	806*	815	959	1,123
Cost of goods and services sold	9*	8	9	8	9*	9	11	14	18*	14	—	—
Selling, general and administrative	219*	243	242	234	288*	277	286	292	302*	319	440	366
Operating income (loss)	150*	99	145	184	142*	24	146	239	211*	193	152	331
Interest expense	1*	1	—	—	—	—	0	0	—	—	3	0
Income tax expense (benefit)	51*	(9)	34	61	60*	7	52	82	86*	49	18	77
Net income (loss)	148*	43	65	130	103*	8	108	210	154*	198	144	207
Earnings per share, basic USD per share	1.50*	0.43	0.64	1.28	1.03*	0.08	1.09	2.11	1.54*	1.97	1.43	2.03
Earnings per share, diluted USD per share	1.40*	0.42	0.63	1.24	1.00*	0.08	1.06	2.04	1.48*	1.91	1.39	1.96
Weighted average shares, basic millions of shares	98*	100	101	101	100*	100	99	99	100*	101	101	102
Weighted average shares, diluted millions of shares	106*	104	104	104	103*	103	101	103	104*	103	104	105

Fiscal quarters (NBIX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	251	396	140	349	233	194	264	340	713	267	332	642
Marketable securities	781	814	899	879	843	749	712	775	767	1,050	57	96
Marketable securities, non-current	688	700	638	644	740	815	874	999	1,063	1,331	92	52
Accounts receivable	439	451	468	481	479	516	596	728	687	768	887	957
Inventory	38	37	43	46	57	59	57	69	69	65	104	66
Total current assets	1,607	1,799	1,670	1,877	1,725	1,638	1,749	2,158	2,523	2,436	1,638	2,008
Property and equipment, net	71	75	80	80	83	87	92	97	90	91	91	92
Right-of-use asset	277	271	263	257	509	502	492	469	455	447	448	437
Goodwill	6	6	6	6	6	—	—	—	6	6	501	501
Total assets	3,251	3,472	3,305	3,535	3,719	3,688	3,890	4,266	4,632	4,906	5,359	5,627
Total current liabilities	655	713	399	430	508	523	546	638	743	832	875	985
Lease liability, non-current	258	253	256	251	455	448	439	428	415	406	402	392
Total liabilities	1,019	1,086	796	816	1,129	1,152	1,196	1,262	1,378	1,499	1,666	1,749
Retained earnings (accumulated deficit)	(157)	(114)	(49)	81	29	(5)	85	294	448	590	724	838
Total stockholders' equity	2,232	2,386	2,509	2,719	2,590	2,536	2,694	3,004	3,253	3,407	3,694	3,879
Total liabilities and equity	3,251	3,472	3,305	3,535	3,719	3,688	3,890	4,266	4,632	4,906	5,359	5,627
Common shares outstanding (cover page) millions of shares	100	101	101	101	100	99	99	100	100	101	102	101

Fiscal quarters (NBIX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	148*	43	65	130	103*	8	108	210	154*	198	144	207
Stock-based compensation	38*	45	43*	42*	66*	53	53*	54*	59*	57	65*	54*
Net cash from operating activities	124*	130	65*	158*	243*	65	102*	228*	388*	146	136*	395*
Purchases of property and equipment	5*	11	12*	8*	7*	11	13*	13*	(2)*	9	8*	12*
Net cash from investing activities	(202)*	(55)	(28)*	25*	(68)*	14	(29)*	(197)*	(53)*	(506)	(135)*	(11)*
Proceeds from issuing common stock	35*	70	16*	26*	10*	32	14*	46*	37*	24	85*	25*
Share repurchases	year only	0	0*	0*	300*	150	18*	0*	0*	54	12*	92*
Net cash from financing activities	35*	70	(293)*	26*	(290)*	(118)	(3)*	46*	37*	(86)	63*	(75)*
Net change in cash	(43)*	145	(257)*	209*	(116)*	(39)	70*	76*	373*	(447)	64*	309*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.